Novartis East Hanover Plans Up to 130 Cuts; Arsenal Biosciences WARN for 58
Two Health Care employers reported workforce reductions: Novartis East Hanover up to 130 roles; Arsenal Biosciences WARN filing for 58 jobs.
Novartis East Hanover Plans Up to 130 Cuts; Arsenal Biosciences WARN for 58
Lede
Reported layoffs
Novartis East Hanover said it intends to cut up to 130 roles at its Basel site, describing the action as a planned workforce reduction rather than completed layoffs, per reporting by Fierce Pharma, BW People, and Medical Dialogues. The company did not provide specific departments, exact timing, or details on severance in the reports; the figure represents a maximum potential headcount reduction, and the announcement was framed as part of internal restructuring measures, according to those outlets.
Arsenal Biosciences, Inc. filed a WARN notice with state regulators that lists 58 employees as affected, per the WARN filing. The filing provides the formal notification of the planned job cuts documented with regulators; no additional summary details were included in the supplied record.
Timing and scope
The supplied records place these notifications within the September 3–September 4, 2026 window for aggregation purposes. The Novartis disclosures were reported by trade and industry outlets named above; the Arsenal Biosciences entry derives from a WARN filing with state regulators.
Closing
Collectively, the two entries account for 188 employees identified in the supplied records for Health Care layoffs during the specified period. Each report is sourced to the cited publications or the WARN filing and provides limited operational detail beyond the headcount figures and the locations or filing origin noted above.